ResearcherLMU KlinikumActive in the last 2 years
Lena Weiss
Matched on ORCID iD 0000-0002-8101-3529; OpenAlex author ID A5007401013. Sources: OpenAlex.
Their work
- Papers
- 6
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 26
2023: 3 papers · 2024: 3 papers
Papers 6
- Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection? Co-author DOI 10.1007/s12094-023-03323-1↗
- Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical trial. Co-author DOI 10.1016/j.ejca.2024.113926↗
- Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis of five clinical trials from two decades … Co-author DOI 10.1016/j.esmoop.2024.102944↗
- Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-γ, TNF-α and PD-1/PD-L1 in comparison … Co-author DOI 10.1007/s00432-022-04112-z↗
- Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich LMU Molecular Tumor Board. Co-author DOI 10.1007/s11523-023-00950-0↗
- Clinical Impact of Structured Post-Operative Surveillance in Resected Pancreatic Adenocarcinoma: Results from a Retrospective Cohort Study. Co-author DOI 10.1159/000528722↗
Closest collaborators
The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Michael Haas · 6 shared papers, 2023–2024 · strength 0.95
- Paper Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical … DOI 10.1016/j.ejca.2024.113926↗
- Paper Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis o… DOI 10.1016/j.esmoop.2024.102944↗
- Paper Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a va… DOI 10.1007/s12094-023-03323-1↗
- Klara Dorman · 6 shared papers, 2023–2024 · strength 0.95
- Paper Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical … DOI 10.1016/j.ejca.2024.113926↗
- Paper Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis o… DOI 10.1016/j.esmoop.2024.102944↗
- Paper Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a va… DOI 10.1007/s12094-023-03323-1↗
- Volker Heinemann · 6 shared papers, 2023–2024 · strength 0.95
- Paper Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical … DOI 10.1016/j.ejca.2024.113926↗
- Paper Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis o… DOI 10.1016/j.esmoop.2024.102944↗
- Paper Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a va… DOI 10.1007/s12094-023-03323-1↗
- Stefan Hubert Boeck · 6 shared papers, 2023–2024 · strength 0.95
- Paper Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical … DOI 10.1016/j.ejca.2024.113926↗
- Paper Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis o… DOI 10.1016/j.esmoop.2024.102944↗
- Paper Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a va… DOI 10.1007/s12094-023-03323-1↗
- Christoph Benedikt Westphalen · 6 shared papers, 2023–2024 · strength 0.95
- Paper Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical … DOI 10.1016/j.ejca.2024.113926↗
- Paper Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis o… DOI 10.1016/j.esmoop.2024.102944↗
- Paper Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a va… DOI 10.1007/s12094-023-03323-1↗
- Danmei Zhang · 5 shared papers, 2023–2024 · strength 0.78
- Paper Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical … DOI 10.1016/j.ejca.2024.113926↗
- Paper Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a va… DOI 10.1007/s12094-023-03323-1↗
- Paper Clinical Impact of Structured Post-Operative Surveillance in Resected Pancreatic Adenocarcinoma: Results from a Retrosp… DOI 10.1159/000528722↗
- Dirk Waldschmidt · 3 shared papers, 2024 · strength 0.52
- Paper Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical … DOI 10.1016/j.ejca.2024.113926↗
- Paper Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis o… DOI 10.1016/j.esmoop.2024.102944↗
- Paper Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a va… DOI 10.1007/s12094-023-03323-1↗
- Julia V. Mayerle · 3 shared papers, 2023–2024 · strength 0.46
- Paper Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis o… DOI 10.1016/j.esmoop.2024.102944↗
- Paper Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a va… DOI 10.1007/s12094-023-03323-1↗
- Paper Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich LMU Molecular Tumor Board. DOI 10.1007/s11523-023-00950-0↗
- Steffen Ormanns · 3 shared papers, 2023 · strength 0.43
- Paper Clinical Impact of Structured Post-Operative Surveillance in Resected Pancreatic Adenocarcinoma: Results from a Retrosp… DOI 10.1159/000528722↗
- Paper Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IF… DOI 10.1007/s00432-022-04112-z↗
- Paper Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich LMU Molecular Tumor Board. DOI 10.1007/s11523-023-00950-0↗
- Michael Ståhl · 2 shared papers, 2024 · strength 0.33
- Paper Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis o… DOI 10.1016/j.esmoop.2024.102944↗
- Paper Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a va… DOI 10.1007/s12094-023-03323-1↗
- Jens Thomas Siveke · 2 shared papers, 2024 · strength 0.33
- Paper Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis o… DOI 10.1016/j.esmoop.2024.102944↗
- Paper Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a va… DOI 10.1007/s12094-023-03323-1↗
- Anke Reinacher‐Schick · 2 shared papers, 2024 · strength 0.33
- Paper Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis o… DOI 10.1016/j.esmoop.2024.102944↗
- Paper Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a va… DOI 10.1007/s12094-023-03323-1↗
- Kathrin Heinrich · 2 shared papers, 2023–2024 · strength 0.32
- Paper Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical … DOI 10.1016/j.ejca.2024.113926↗
- Paper Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich LMU Molecular Tumor Board. DOI 10.1007/s11523-023-00950-0↗
- Stephan Krüger · 2 shared papers, 2023 · strength 0.30
- Paper Clinical Impact of Structured Post-Operative Surveillance in Resected Pancreatic Adenocarcinoma: Results from a Retrosp… DOI 10.1159/000528722↗
- Paper Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IF… DOI 10.1007/s00432-022-04112-z↗
- Jens Werner · 2 shared papers, 2023 · strength 0.29
- Victoria Probst · 1 shared paper, 2024 · strength 0.18
- Michael Quante · 1 shared paper, 2024 · strength 0.18
- Leonie Gebauer · 1 shared paper, 2023 · strength 0.16
- Michael Guenther · 1 shared paper, 2023 · strength 0.14
- Jens Martin Werner · 1 shared paper, 2023 · strength 0.14
- Stefan Holdenrieder · 1 shared paper, 2023 · strength 0.14
- Bernhard Willibald Renz · 1 shared paper, 2023 · strength 0.13
- Elisabetta Goni · 1 shared paper, 2023 · strength 0.13
- Jan Goesta D’Haese · 1 shared paper, 2023 · strength 0.13
- Frederick Klauschen · 1 shared paper, 2023 · strength 0.13
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.